The John Quale Travel Fellowship Program is a special opportunity for early career investigators interested in bladder cancer research to attend the annual Bladder Cancer Think Tank Meeting. The application process is now closed for 2014.
The $1,500 travel fellowships awarded each year are intended to defray travel-related costs for attending the meeting. Hosted by the Bladder Cancer Advocacy Network (BCAN), the primary mission of this meeting is to enhance collaboration among physicians and researchers who are dedicated to the prevention, diagnosis, and treatment of bladder cancer. This is a unique opportunity to meet and learn from leaders in the field. The Travel Fellowship Program seeks to engage more early-career individuals with interests related to bladder cancer including basic scientists, urologists, oncologists, and pathologists. Please contact BCAN at email@example.com if you have questions.
2013 Travel Fellows
- Richard Bambury, MD, BCh, BAO, Memorial Sloan-Kettering Cancer Center
- Sima Porten, MD, MPH, MD Anderson Cancer Center
- Srinivas Vourganti, MD, National Cancer Institute
- Daniel Willis, MD, MD Anderson Cancer Center
From left to right: Richard Bambury, Srinivas Vourganti, Sima Porten, Daniel Willis
2012 John Quale Travel Fellows
2011 Travel Fellows
(left to right: Sandip Prasad, Kenneth Nepple, Steven Smith, Meng Chen)
Meng Chen, PhD, a postdoctoral fellow in the department of epidemiology at the University of Texas MD Anderson Cancer Center, presented on a potential genetic marker of susceptibility to bladder cancer, which also correlates with telomere length.
Kenneth Nepple, MD, a fellow in urologic oncology at Washington University in St. Louis, discussed hospital readmission rates (whether patients have to return to the hospital within 90 days) for patients after a radical cystectomy, and what factors might affect readmission rates.
Sandip Prasad, MD, a Society of Urologic Oncology Fellow at the University of Chicago, talked about identifying “hot spots” for bladder cancer – geographic areas where bladder cancer is more common than we would expect – and how we can compare those hot spots to what carcinogens people in that area might have been exposed to.
Steven Smith, MD, PhD, a pathology resident at the University of Michigan, presented on the potential use of molecular biology to identify which patients are likely to respond to chemotherapy.
(left to right: Kilian Gust, Amit Patel, Peter O’Donnell, Heather Honorѐ Goltz, Steven Smith, Sandip Prasad, William Brandt, Kenneth Nepple, Meng Chen)
Travel Fellows 2010
Andrew Feifer, MD, a second year fellow in urologic oncology at Memorial Sloan-Kettering Cancer Center, presented on a survey examining chemotherapy use in bladder cancer patients.
Heather Honorѐ Goltz, PhD, LMSW, a NIDDK KURe Scholar in the VA Health Services Research and Development Center of Excellence at the Michael E. DeBakay VA Medical Center, spoke about health literacy in bladder cancer patients.
William Brandt, PhD, a post-doctoral fellow in Pathology at Johns Hopkins University, discussed efforts to target the Notch pathway in bladder cancer stem cells.
Kilian Gust, MD, a post-doctoral fellow at the Vancouver Prostate Centre, presented research on the differential expression of Notch receptors in bladder cancer.
2009 Travel Fellows
Gayathri Chadalapaka, PhD
David DeGraff, PhD
Peter O’Donnell, MD
Amit Patel, MD